Aspyrian Therapeutics Inc. Announces FDA Acceptance of an Investigational New Drug Application for RM-1929, a First-in-Class, Precision-Targeted Therapy for Cancer

SAN DIEGO, May 12, 2015 -- (Healthcare Sales & Marketing Network) -- Aspyrian Therapeutics Inc., a drug development company creating precision-targeted therapies to treat cancer based on its proprietary Photoimmunotherapy platform, today announced the U.S... Biopharmaceuticals, Oncology, FDAAspyrian Therapeutics, Photoimmunotherapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news